US Broker Ratings

COMPASS Pathways Plc (CMPS) Stock Analysis: A Look at a Promising 130% Upside in Mental Health Innovation

COMPASS Pathways Plc (NASDAQ: CMPS) is gaining attention in the healthcare sector, particularly among investors intrigued by its role in revolutionizing mental health treatment. With a..

Tyra Biosciences, Inc. (TYRA): Investor Outlook on a Promising Biotech with 15.68% Upside Potential

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company headquartered in Carlsbad, California, is garnering significant attention in the healthcare sector. With a market capitalization of..

PureTech Health (PRTC) Stock Analysis: Unveiling the 542.7% Revenue Growth in Biotech Innovation

In the fast-paced world of biotechnology, PureTech Health plc (NASDAQ: PRTC) is emerging as a compelling player, sparking interest with its remarkable 542.7% revenue growth. As..

InnovAge Holding Corp. (INNV) Stock Analysis: Navigating Through Healthcare Challenges with a 15.10% Revenue Growth

InnovAge Holding Corp. (INNV) has carved a niche within the healthcare sector, specializing in medical care facilities tailored for seniors. The company, with a market capitalization..

Valneva SE (VALN) Stock Analysis: Exploring a 28% Upside Potential Amidst Biotech Challenges

Valneva SE (NASDAQ: VALN), a prominent player in the biotechnology sector, is garnering attention for its innovative vaccine solutions targeting infectious diseases. Based in Saint-Herblain, France,..

Fortrea Holdings Inc. (FTRE) Stock Analysis: Navigating Opportunities with Key Analyst Ratings

Fortrea Holdings Inc. (NASDAQ: FTRE), a notable player in the healthcare sector, specifically within the biotechnology industry, has captured investor attention with its dynamic position in..

uniQure N.V. (QURE): Investor Outlook on Potential 149.62% Upside in Biotech

Investors are turning their attention to uniQure N.V. (NASDAQ: QURE), a biotechnology company with a strong focus on developing gene therapies for rare and devastating diseases...

Oculis Holding AG (OCS) Stock Analysis: Uncovering an 85.74% Upside Potential

Oculis Holding AG (NASDAQ: OCS), a Switzerland-based clinical-stage biopharmaceutical company, is capturing the attention of investors with its promising pipeline of ophthalmic drug candidates and a..

Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 53.95% Potential Upside in the Biotech Sector

Upstream Bio, Inc. (UPB) is capturing the attention of investors with its promising potential upside of 53.95%. Operating within the dynamic biotechnology sector, this U.S.-based company,..

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Unraveling the 149.93% Potential Upside

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is emerging as a fascinating prospect in the biotechnology sector, capturing the attention of investors with its strategic focus on rare..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Exploring a 13.36% Potential Upside in the Healthcare Sector

Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a key player in the healthcare sector, is gaining significant attention from investors due to its strong growth trajectory and promising..

Intellia Therapeutics, Inc. (NTLA): Investor Outlook with an 87.64% Potential Upside

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneering player in the biotechnology sector, is capturing the attention of investors with its remarkable potential upside of 87.64%. As..

Beta Bionics, Inc. (BBNX) Stock Analysis: Harnessing a 78.75% Upside Potential in the Medical Devices Sector

For investors with an eye on the healthcare sector, Beta Bionics, Inc. (NASDAQ: BBNX) offers a compelling opportunity in the medical devices industry. With a market..

SIGA Technologies Inc. (SIGA) Stock Analysis: Evaluating Growth Potential Amidst Revenue Challenges

SIGA Technologies Inc. (NASDAQ: SIGA) operates within the healthcare sector, specifically focusing on drug manufacturing for specialty and generic markets. With a market capitalization of $473.35..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: A Look at Its 18.90% Potential Upside

Maze Therapeutics, Inc. (MAZE) stands out in the biotechnology sector with its promising pipeline of precision medicines. As a clinical-stage biopharmaceutical company, Maze Therapeutics is primarily..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenges with a 4.38% Potential Upside

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), headquartered in Boston, Massachusetts, is a pioneering entity at the forefront of biotechnology innovation. Specializing in cell programming, Ginkgo Bioworks..

Embecta Corp. (EMBC) Investor Outlook: Exploring a Potential 32% Upside Amidst Healthcare Sector Challenges

Embecta Corp. (EMBC), a prominent player in the healthcare sector, is gaining attention from investors seeking opportunities in the medical instruments and supplies industry. Specializing in..

Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A Biotech Gem with Over 100% Potential Upside

Zenas BioPharma, Inc. (NASDAQ: ZBIO), a promising player in the biotechnology sector, has been making waves with its innovative approach to immunology-based therapies. The company, which..

Arbutus Biopharma (ABUS) Stock Analysis: A Potential 20% Upside for Risk-Tolerant Investors

Arbutus Biopharma Corporation (NASDAQ: ABUS), a clinical-stage biopharmaceutical company, is drawing attention in the healthcare sector with a promising pipeline aimed at combating chronic Hepatitis B..

Definitive Healthcare Corp. (DH)

⚠️ No article content returned.

..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds